New Mexico State University (NMSU)

Testing millions for coronavirus quickly

NMSU alum, healthcare entrepreneur develops rapid diagnostic test for active COVID-19

Newswise — A young health care entrepreneur, a New Mexico native who grew up just south of Las Cruces, may hold the key to testing millions of Americans to see if they are infected and spreading the coronavirus.

His company, E25Bio, is currently pushing to get the Federal Drug Administration’s Emergency Use Authorization by September 1 to launch on the market.

“To my knowledge, E25Bio is among a few companies in the world that have produced direct antigen rapid tests (DART) for SARS-COV-2 detection,” said Bobby Brooke Herrera, E25Bio Interim CEO and Chief Science Officer. “The E25Bio DART enables detection of active infections in a rapid way to triage the severely infectious and ill from those who are uninfected.”

The E235Bio DART is a less expensive, paper-based test that can deliver COVID-19 results in 15 minutes or less. The test is similar to a pregnancy test with no moving parts, no machinery, and results in a visual readout.

“There are many rapid antibody-based tests that are coming to market,” Herrera said. “These tests do not identify active COVID-19 infections, but rather let patients know they were infected.”  

Molecular diagnostic methods such as gold standard polymerase chain reaction (PCR) require laboratories to charge $50 to $100 or more per patient. Rapid tests such as those produced by E25Bio cost significantly less and don’t require lab processing.

Herrera grew up in San Miguel, New Mexico, and earned his bachelor’s degree in biology at NMSU in 2012. He earned a master’s degree at Harvard’s Divinity School then pursued his Ph.D. at Harvard’s T.H. Chan School of Public Health, where he worked with professor Phyllis Kanki, a pioneer in the research of HIV1 and HIV2.

In 2018, he co-founded his company with career MIT researcher Irene Bosch and MIT professor Lee Gehrke. Last fall, Herrera was named by Forbes magazine among the top 30 young entrepreneurs for 2020 creating solutions to some of health care’s most pressing problems.

By July 2020, the company has raised $12.92 million in funding from Venture Capital, National Institutes of Health, and the Bill and Melinda Gates Foundation.

E25Bio’s DART for COVID-19 is low cost and scalable. However, part of the challenge is that antigen-based tests have lower sensitivity as compared to PCR tests. A recent op-ed in New York Times, written by Herrera’s colleague Harvard professor Michael Mina, has called for the FDA to prioritize low-cost, scalable diagnostic solutions such as the paper-based strip being developed by E25Bio. Modeling studies show that frequency and coverage of diagnostic testing is more important than analytical sensitivity. 

“Our manufacturers can produce millions of tests per week,” Herrera said. “This is in stark contrast to PCR, which any one hospital can only test up to 5,000-10,000 patients per day.

“Additionally, the E25Bio DART enables contact tracing, as it can paired with a mobile phone app to report test results and epidemiological data in real-time to the cloud. Diagnosis during the active phase of infection is important because one is able to then isolate before transmitting the virus to others.”

Herrera’s study of both religion and science has influenced his social justice approach to public health.

“I'm passionate about the basic biology of infectious disease pathogenesis, but also I’m intrigued by the anthropology or the human side of those infected with these microorganisms,” Herrera said. “If we can understand structural determinants and human behavior and combine that knowledge with rigorous science and experimentation, we will be able to develop and implement more robust vaccines and diagnostic tests.

“We need to get to a place where there is a just public health system.”



Filters close

Showing results

110 of 4219
Released: 4-Dec-2020 4:30 PM EST
New review confirms disproportionate impact of COVID-19 on Black, Hispanic populations
Oregon Health & Science University

Black and Hispanic populations are disproportionately affected by COVID-19, according to a systematic review published this week.

Newswise: 250647_web.jpg
Released: 4-Dec-2020 4:05 PM EST
For nationalistic regimes, similar COVID-19 policies are the sincerest form of flattery
University of Texas at Arlington

Analysis from a University of Texas at Arlington assistant professor of public policy suggests that nationalistic governments around the globe are more likely to copy other nationalistic governments in responding to the current pandemic.

Released: 4-Dec-2020 3:15 PM EST
New Study Finds Once Hospitalized, Black Patients with COVID-19 Have Lower Risk of Death than White Patients
NYU Langone Health

A team of investigators at NYU Langone Health has found that once hospitalized, Black patients (after controlling for other serious health conditions and neighborhood income) were less likely to have severe illness, die, or be discharged to hospice compared to White patients.

Released: 4-Dec-2020 2:35 PM EST
AANA Commends CDC on Prioritizing COVID-19 Vaccine Distribution to Healthcare Personnel
American Association of Nurse Anesthetists (AANA)

The American Association of Nurse Anesthetists (AANA) commends the U.S. Centers for Disease Control and Prevention’s (CDC's) team of advisors on prioritizing frontline healthcare personnel and residents of long-term facilities for the first phase of the COVID-19 vaccine distribution.

Released: 4-Dec-2020 1:50 PM EST
COVID-19 in Victorian schools and childcare mainly driven by community transmission
Murdoch Childrens Research Institute

Analysis of Victorian data by the Murdoch Children's Research Institute suggests that COVID-19 cases in schools and childcare were mainly driven by community transmission

Released: 4-Dec-2020 12:20 PM EST
Identifying markers of COVID-19 infection using blood tests
University of Seville

Researchers from the Institute of Biomedicine of Seville (IBIS) have presented a study carried out in the Clinical Biochemistry Service of the Virgen del Rocío University Hospital which identifies the values for six biochemical biomarkers that indicate a patient may be infected with SARS-COV-2 (COVID-19).

Released: 4-Dec-2020 12:05 PM EST
Research confirms crucial monitoring assessment is effective for patients with COVID-19
University of Portsmouth

A combined research team from the Universities of Portsmouth and Bournemouth and Portsmouth Hospitals University NHS Trust has shown that an assessment score used to measure a patient's severity of illness can be applied to patients with Covid-19 without modification.

Newswise:Video Embedded flccc-alliance-calls-on-national-health-authorities-to-immediately-review-medical-evidence-showing-the-efficacy-of-ivermectin-for-the-prevention-of-covid-19-and-as-an-early-outpatient-treatment
Released: 4-Dec-2020 12:00 PM EST
FLCCC Alliance Calls on National Health Authorities to Immediately Review Medical Evidence Showing the Efficacy of Ivermectin for the Prevention of COVID-19 and as an Early Outpatient Treatment
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

“Following the swi. review— and subsequent guidance— by the NIH and theCDC of Ivermectin, we expect that Ivermectin’s widespread, immediate use willallow for a rapid and safe re-opening of businesses and schools across the nation—and quickly reduce the strain on overwhelmed ICUs.” —FLCCC Alliance

Released: 4-Dec-2020 11:50 AM EST
Immunity passports: Ethical conflict and opportunity
University of the Basque Country

Immunity passports are a means of registering whether an individual has developed immunity to COVID-19 and is therefore unlikely to either catch or spread the disease.

Showing results

110 of 4219